The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug: comments on the article by Söderlin et al

Park, Sung Jin; Ji, Shin

doi:10.3109/03009742.2012.698394

Cited by 7 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The univariate logistic regression model results indicated that smoking is an excellent predictor of patients' predisposition to be non-responders to etanercept in Iraqi patients with rheumatoid arthritis. This result is comparable to previous studies, which confirm that smokers with rheumatoid arthritis are less likely to respond to an anti-TNF agent (21)(22)(23).…”

Section: Discussionsupporting

confidence: 90%

Epidemiological and Clinical Factors Affecting the Response to Etanercept Among Patients with Rheumatoid Arthritis

Mohammed¹,

Zalzala²,

Gorial³

2022

jpc

View full text Add to dashboard Cite

Background: This study aimed to inspect the association between the response to etanercept among patients with rheumatoid arthritis and several epidemiological and clinical variables and medication adherence, as measured by medication possession ratio (MPR). Methods: A cohort study that enrolls 120 active rheumatoid arthritis patients. The baseline values of disease activity score for 28 joints (DAS28) score,erythrocyte sedimmintation rate (ESR), WBC, tender joints count (TJC), swelling joints counts (SJC), and medication adherence, as measured by medication possession ratio (MPR), were identified. All patients received etanercept treatment for three months, and then the clinical response to etanercept was assessed after the end of the three months duration. Factors affecting clinical response were evaluated by univariate and multivariate logistic regression analysis. The predictive performance of a single independent predictor was then assessed using a receiver operating characteristic (ROC) curve. Results: The results of the univariate logistic regression model showed that the smoking, disease duration, baseline DAS28, and MPR could predict the patients' proclivity for being non-responder. The multivariate logistic regression model showed that only baseline DAS28 (P< 0.0001, OR=32.239, 95%CI: 4.941–210.338) and MPR (P=0.002, OR=0.00063, 95%CI: 0.00001–0.032) were independent predictive factors for the tendency of patients to be non-responder. ROC curve analysis disclosed that baseline ESR and DAS28 have a good area under the curve (AUC) with the optimal cut-off for the baseline ESR threshold was 52 mm/hr., whereas the baseline DAS28 threshold was 5.79. Conclusion: Current smoking is the main epidemiological factor that can predict the tendency for being non-responder. The potential of baseline ESR and DAS28 values as biomarkers for clinical response to etanercept in RA patients was identified by Receiver operating characteristic(ROC) analysis.

show abstract

Section: Discussionsupporting

confidence: 90%

Epidemiological and Clinical Factors Affecting the Response to Etanercept Among Patients with Rheumatoid Arthritis

Mohammed¹,

Zalzala²,

Gorial³

2022

jpc

View full text Add to dashboard Cite

show abstract

“…In RA, several studies have reported poorer TNFi adherence and treatment response among smokers 6 20–23. It has been suggested that smoking causes higher levels of TNF-α and other inflammatory markers,22 35 36 altered bioavailability of antirheumatic drugs, cutaneous vasoconstriction and slower absorption from subcutaneous injection, or increased basal metabolic rate 20 37 38. Few studies analysed the impact of smoking according to type of TNFi, and found that smoking mainly affected infliximab treatment 6 22.…”

Section: Discussionmentioning

confidence: 99%

Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry

Højgaard

Glintborg

Hetland

et al. 2015

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

show abstract

“…Moreover, Kuliala et al showed that a low serum sIL-2R level predicts rapid response to infliximab, a TNF-α antagonist [ 91 ]. Moreover, Shin et al suggested that sIL-2R can influence the response to infliximab in RA patients [ 92 ]. It is possible that IL-2-sIL-2R system activation affects the response to TNF-α antagonist treatment of RA patients who smoke [ 92 ].…”

Section: Effect Of Smoking On Drug Response In Ramentioning

confidence: 99%

“…Moreover, Shin et al suggested that sIL-2R can influence the response to infliximab in RA patients [ 92 ]. It is possible that IL-2-sIL-2R system activation affects the response to TNF-α antagonist treatment of RA patients who smoke [ 92 ].…”

Section: Effect Of Smoking On Drug Response In Ramentioning

confidence: 99%

Smoking and Rheumatoid Arthritis

Chang

Yang

Kim

et al. 2014

IJMS

256

147

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic inflammatory disease caused by both genetic and environmental factors. Smoking has been implicated as one of the most important extrinsic risk factors for its development and severity. Recent developments have shed light on the pathophysiology of RA in smokers, including oxidative stress, inflammation, autoantibody formation and epigenetic changes. The association of smoking and the development of RA have been demonstrated through epidemiologic studies, as well as through in vivo and animal models of RA. With increased use of biological agents in addition to standard disease-modifying antirheumatic drugs (DMARDs), there has been interest in how smoking affects drug response in RA treatment. Recent evidence suggests the response and drug survival in people treated with anti-tumour necrosis factor (anti-TNF) therapy is poorer in heavy smokers, and possible immunological mechanisms for this effect are presented in the current paper.

show abstract

The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug: comments on the article by Söderlin et al

Cited by 7 publications

References 7 publications

Epidemiological and Clinical Factors Affecting the Response to Etanercept Among Patients with Rheumatoid Arthritis

Epidemiological and Clinical Factors Affecting the Response to Etanercept Among Patients with Rheumatoid Arthritis

Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry

Smoking and Rheumatoid Arthritis

Contact Info

Product

Resources

About